Skyrizi came out on top with the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands. The AbbVie treatment for psoriasis, Crohn’s disease and psoriatic arthritis finished in first ...

As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...

AbbVie is once again the top spender on pharma TV ads, narrowly beating April's winner, Rexulti. That’s according to the latest data from real-time TV ad trackers at iSpot.TV, who crunched May’s ...

Additionally, Ro was the fifth-most seen brand during the 2025 World Series, with three separate spots — including its Serena Williams-led GLP-1 ad.

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...

AbbVie's high-growth investment thesis is undeniable indeed, despite Humira's painful patent expiry and the erosion observed in its sales thus far. Our optimism arises from Skyrizi's/Rinvoq's ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know ...